DiObex is a privately held biotechnology company engaged in the development of novel products for the treatment of metabolic diseases.

Our pipeline includes products targeted at significant unmet medical needs in metabolic disorders including type 1 and type 2 diabetes, dyslipidemia, obesity, and diabetic nephropathy.